PPD01.02 Repotrectinib in Patients With ROS1 Fusion-Positive (ROS1+) NSCLC: Update From the Pivotal Phase 1/2 TRIDENT-1 Trial
Alexander Drilon(Memorial Sloan Kettering Cancer Center), Byoung Chul Cho(Yonsei University), Benjamin Besse(Université Paris-Sud), Kōichi Goto(National Cancer Center Hospital East), Benjamin Solomon(Peter MacCallum Cancer Centre), Sang‐We Kim(Ulsan College), Denise Trone(Bristol-Myers Squibb (Belgium)), Sanjay Popat(Royal Marsden Hospital), Rafał Dziadziuszko(Gdańsk Medical University), Minal Mehta(Millennium Engineering and Integration (United States)), Adrianus J. de Langen(The Netherlands Cancer Institute), Parneet Cheema, Misako Nagasaka(University of California, Irvine), Felipe Ades(Bristol-Myers Squibb (United States)), Vamsidhar Velcheti(Yale University), C. Calvet(Bristol-Myers Squibb (United States)), Nong Yang(Hunan Cancer Hospital), Shanna Stopatschinskaja(Bristol-Myers Squibb (Belgium)), D. Ross Camidge(Odense University Hospital), W. Marston Linehan(Massachusetts General Hospital), Enriqueta Felip(Universitat Autònoma de Barcelona), Jürgen Wolf(Memorial Sloan Kettering Cancer Center), Shun Lu(Shanghai Chest Hospital), Ki Hyeong Lee(University of Ulsan), Steven Kao(Chris O’Brien Lifehouse), Christoph Springfeld(Heidelberg University)
Cited by 0
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k